CJ CheilJedang Partners with US Biotech Emion to Develop 'Muscle Loss Improvement Solution'

First Global Collaboration of Future Food FNT Division
Developing Nutrition Ingredients to Help Symptoms of Muscle Weakness

[Asia Economy Reporter Eunmo Koo] CJ CheilJedang's newly established FNT (Food & Nutrition Tech) business division, created to secure future growth engines, is officially launching its overseas nutrition market expansion through its first global collaboration.

CJ CheilJedang announced on the 6th that it signed a 'Ursolic Acid Utilization License Agreement' with the U.S. healthcare biotech company Emmyon at CJ CheilJedang headquarters in Jung-gu, Seoul. Key executives from both companies attended, including CJ CheilJedang CEO Eunseok Choi, FNT Business Division Head Haeryong Choi, and Emmyon CEO Christopher Adams.

Emmyon, founded in 2012, is a U.S. startup specializing in research related to musculoskeletal health. It holds numerous technology patents that utilize natural substances such as 'Ursolic Acid' to enhance muscle strength and muscle metabolism. The founder and CEO, Dr. Adams, is a medical doctor affiliated with the Mayo Clinic and an authority in skeletal muscle atrophy, diabetes, and obesity.

Through this agreement, CJ CheilJedang can now develop products using Emmyon's patents related to Ursolic Acid. Ursolic Acid is a substance abundantly found in apple peels and rosemary, effective in improving muscle atrophy symptoms, muscle formation, and increasing muscle mass. CJ CheilJedang plans to use this patent to develop nutrition ingredients that prevent and improve sarcopenia and provide total solutions?including manufacturing and raw material application technologies?to global clients producing health functional foods.

A CJ CheilJedang official stated, "This contract is significant as it is the first global collaboration since the launch of the FNT business division," adding, "We will develop customized nutrition solutions for various diseases such as sarcopenia, obesity, and diabetes, and present them to global customers."